Inventiva Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.

Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Inventiva S.A.

Country	France
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	123
CEO	Frederic Cren

Contact Details

Address: 50 rue de Dijon Daix, 21121 France
Phone	33 3 80 44 75 00
Website	inventivapharma.com

Stock Details

Ticker Symbol	IVA
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0013233012
SIC Code	2836

Key Executives

Name	Position
Dr. Pierre Broqua Ph.D.	Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer and Director
Frederic Cren	Co-Founder, Chief Executive Officer and Chairman
Jean Volatier	Deputy GM and Chief Financial Officer
Alice Roudot-Ketelers Pharm.D.	Chief Operating Officer
Eric Duranson L.L.M.	General Counsel
Nathalie Harroy	Head of Human Resources
Dr. Kristina Meyer Ph.D.	Executive Vice President and Business Development and Alliance Management
Dr. Michael Cooreman	Chief Medical Officer
Pascaline Clerc Ph.D.	Executive Vice President of Strategy and Corporate Affairs